Clinical trials: Prostate Cancer, Castration Resistant
Advanced Prostate Cancer
A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer
The purpose of the protocol is to assess the rate of castration resistance, disease progression and overall survival over a 3-year period post-androgen deprivation therapy (ADT) induction in a study cohort of patients with…
- Trial name
- TRIPTOCARE LT (NCT01383863)
- Where
- 35 sites in Denmark, France and 5 more
- Volunteers
- 180 people
- Sponsor
- Ipsen
Metastatic Castration Resistant Prostate Cancer
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment…
- Trial name
- TRITON3 (NCT02975934)
- Testing
- Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel
- Where
- 150 sites in United States, Australia and 10 more
- Volunteers
- 405 people
- Sponsor
- pharmaand GmbH
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
The purpose of this study is to evaluate the safety and activity of BPX-601 CAR-T cells in participants with previously treated advanced solid tumors (prostate) expressing high levels of prostate stem cell antigen (PSCA).
- Trial name
- NCT02744287
- Testing
- BPX-601, Rimiducid
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals
Castration-Resistant Prostatic Neoplasms
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the safety of the combination of cetrelimab, with apalutamide and to define a population of participants with metastatic castration-resistant prostate cancer (mCRPC) who respond to…
- Trial name
- NCT03551782
- Testing
- Cetrelimab 480 mg, Apalutamide 240 mg
- Where
- 34 sites in United States, Belgium and 5 more
- Volunteers
- 33 people
- Sponsor
- Janssen Research & Development, LLC
CRPC, Prostate Cancer
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety BIND-014 in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT01812746
- Testing
- BIND-014
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- BIND Therapeutics
Metastatic Castration-resistant Prostate Cancer
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.
- Trial name
- SYNERGY-201 (NCT06228053)
- Testing
- SX-682, Enzalutamide
- Where
- 6 sites in United States
- Volunteers
- 53 people
- Sponsor
- Syntrix Biosystems, Inc.
Prostate Cancer, Castration Resistant
Multi-academic Center Study of Xofigo Patients
The study will be conducted from a real-world perspective to describe treatment sequences involving radium-223 and chemotherapy in patients with metastatic castrate resistant prostate cancer (mCRPC) and assess overall survival…
- Trial name
- NCT03419442
- Testing
- Xofigo, Taxotere, Jevtana
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Bayer
Prostate Neoplasms
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to determine the effect of abiraterone acetate plus prednisone on the conduction of electric charges within the heart and to determine the blood levels of abiraterone acetate following administration…
- Trial name
- NCT00910754
- Testing
- Abiraterone acetate, Prednisone
- Where
- 8 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Cancer, Castration-Resistant
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Researchers in this study want to compare the effects of drug darolutamide and drug enzalutamide on physical function, including balance and daily activity, in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- DaroAcT (NCT04157088)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Enzalutamide
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bayer
High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma
Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System
This study is designed to evaluate the presence and numbers of circulating tumor cells (CTCs) and cancer related gene expression levels in subjects with localized high-risk prostate cancer (HRLPC) and from subjects with…
- Conditions
- High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
- Trial name
- CHARTER (NCT05437679)
- Testing
- Blood collection
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Angle plc
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
Metastatic Castration-resistant Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- rechARge (NCT06764485)
- Testing
- BMS-986365, Enzalutamide, Abiraterone
- Where
- 227 sites in United States, Argentina and 24 more
- Volunteers
- 960 people
- Sponsor
- Celgene
Metastatic Castration-resistant Prostate Cancer
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant…
- Trial name
- NCT05171816
- Testing
- olaparib, abiraterone acetate
- Where
- 26 sites in China
- Volunteers
- 110 people
- Sponsor
- AstraZeneca
Prostate Cancer
A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
The aim of this study was to assess the characteristics, treatment patterns, and clinical outcomes among metastatic castration-resistant prostate cancer (mCRPC) patients in the United States (US) who were treated with…
- Trial name
- NCT07477756
- Where
- United States
- Volunteers
- 1,247 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Castration-Resistant Prostatic Cancer
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
- Trial name
- MAGNITUDE (NCT03748641)
- Testing
- Niraparib, Abiraterone Acetate, Prednisone
- Where
- 318 sites in United States, Argentina and 27 more
- Volunteers
- 765 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Castration Resistant Prostate Cancer (mCRPC)
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other…
- Trial name
- EPIX (NCT04516161)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- United States
- Volunteers
- 1,180 people
- Sponsor
- Bayer
Prostatic Neoplasms
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with…
- Trial name
- NCT01618370
- Testing
- Radium-223 dichloride (BAY88-8223)
- Where
- 215 sites in Belgium, Canada and 17 more
- Volunteers
- 705 people
- Sponsor
- Bayer
Prostate Cancer
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Protocol G200712 is a Phase II, exploratory study to assess the effects of GTx-758 on serum prostate specific antigen (PSA) response ans serum PSA progression in men with Metastatic Castration Resistant Prostate Cancer (mCRPC) on…
- Trial name
- NCT01615120
- Testing
- GTx-758 125 mg, GTx-758 250 mg
- Where
- 26 sites in United States
- Volunteers
- 77 people
- Sponsor
- GTx
Prostate Neoplasms, Prostate Cancer
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the maximum safe dose of abiraterone acetate administered in combination with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- mCRPC (NCT01400555)
- Testing
- Cohort 4, Cohort 3, Cohort 2
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cougar Biotechnology, Inc.